AC Immune SA (ACIU)
NASDAQ: ACIU · Real-Time Price · USD
2.820
+0.050 (1.81%)
At close: May 19, 2026, 4:00 PM EDT
2.774
-0.046 (-1.63%)
After-hours: May 19, 2026, 5:44 PM EDT
AC Immune Revenue
AC Immune had revenue of 1.12M CHF in the quarter ending March 31, 2026, with 13.03% growth. This brings the company's revenue in the last twelve months to 3.70M, down -86.92% year-over-year. In the year 2025, AC Immune had annual revenue of 3.57M, down -86.92%.
Revenue (ttm)
3.70M CHF
Revenue Growth
-86.92%
P/S Ratio
60.40
Revenue / Employee
30,344 CHF
Employees
122
Market Cap
279.75M USD
Revenue Chart
* This company reports financials in CHF.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.57M | -23.74M | -86.92% |
| Dec 31, 2024 | 27.31M | 12.51M | 84.51% |
| Dec 31, 2023 | 14.80M | 10.87M | 276.14% |
| Dec 31, 2022 | 3.94M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | 15.43M | -95.03M | -86.03% |
| Dec 31, 2019 | 110.46M | 103.54M | 1,498.03% |
| Dec 31, 2018 | 6.91M | -13.34M | -65.88% |
| Dec 31, 2017 | 20.26M | -2.96M | -12.75% |
| Dec 31, 2016 | 23.21M | -15.88M | -40.61% |
| Dec 31, 2015 | 39.09M | 8.82M | 29.14% |
| Dec 31, 2014 | 30.27M | 21.63M | 250.46% |
| Dec 31, 2013 | 8.64M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| MacroGenics | 157.08M |
| REGENXBIO | 87.82M |
| Cellectis | 75.11M |
| Armata Pharmaceuticals | 5.20M |
| Silence Therapeutics | 839.00K |
| Inhibikase Therapeutics | 1.00 |
ACIU News
- 4 days ago - Davos Alzheimer's Collaborative Celebrates Andrea Pfeifer, Retiring CEO of AC Immune, for Her Contributions to Alzheimer's Policy, Research and Care - GlobeNewsWire
- 7 days ago - AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM - GlobeNewsWire
- 19 days ago - AC Immune reports Q1 EPS (15c), consensus (14c) - TheFly
- 19 days ago - AC Immune First Quarter 2026 Financial and Corporate Updates - GlobeNewsWire
- 19 days ago - AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease - GlobeNewsWire
- 19 days ago - AC Immune Earnings release: Q1 2026 - Filings
- 5 weeks ago - AC Immune Slides: Investor presentation - Filings
- 6 weeks ago - Leerink calls AC Immune- Eli Lilly Tau amendment ‘great news’ - TheFly